Executive Director Report
November 2026

Licensing

License Type	Active	Detail	Renewal	Issued Last 30 Days
Pharmacist	24,546	Emeritus – 612		104
Pharmacy Intern	2,602			45
Pharmacy Technician	29,113	Trainee – 7,755 Registered – 7,792 Certified – 13,566 Active/Restricted – 21		795
Terminal Distributor	22,778			136
Drug Distributor	2,371			8
Home Medical Equipment	818	License – 156 Registration – 662		15

Counts as of 10/26/2026

Compliance

STATISTICS – SEPTEMBER 2026

In-Take Panel Statistics

Cases Assigned	9/01	9/04	9/08	9/11	9/15	9/18	9/22	9/25	9/29
Consumer Complaint	3	9	3	7	3	5	5	1	5
Minimum Qualifications of TDDD/WDDD	2	3	4	4	1	10	6	3	4
Questionable Dispensing		1		1	1	2		1	1
Working Conditions/Minimum Standards				2	1	1	2	1	1
Error in Dispensing	1	2	4	3	2	1		2	2
Illegal Processing of Drug Documents	1			1	5	1	1	2	
Adulterated Drugs						1			
Unprofessional Conduct/Gross Immorality		1		1				1	
Violation of Patient Confidentiality				1				1	
Operating without a License	1								1
Fraud			1						
Background Investigation	1				1	1	1		
OARRS Complaint				1					
Illegal Drug Sales		1	2					1	4
Abusing, Addicted, and/or Unfit		1					1	1	
Questionable Prescribing	1			1		1			
Drug Security		1					2		
Practicing Pharmacy without a License			1						
Trafficking in Drugs	1			1					1
Error in Administration	1								
Compounding Violations		1							
Failure to Perform DUR						1			
Questionable Administration							1		
Total	**1**	**20**	**15**	**23**	**14**	**24**	**19**	**14**	**19**

All Open Cases	New Cases Opened in Past 30 Days (September)	Number of Summary Suspensions in September	Cases Closed in Past 30 Days (September)
572	227	8	271

Top 10 Cases Opened in September 2026

Case Type	Cases Opened
Drug Security	26
Minimum Qualifications of TDDD/WDDD	23
Suspicious Purchases	20
Error in Dispensing	19
Theft of Drugs	15
Background Investigation	13
Consumer Complaint	12
Trafficking in Drugs	9
Questionable Dispensing	7
Working Conditions/Minimum Standards	7

Investigations Summary (September)

Monthly Investigations Summary	Total
Current open cases (as of October 28, 2026)	572
Cases opened in September 2026	227
Complaints received	160
Cases opened from complaints (Intake)	99
Cases opened in the field (Self-Initiated)	45
Admin. cases referred to OBP Legal Department	34
Court orders received	-
Criminal convictions	1
Intervention in Lieu of Conviction (ILC)	2
Criminal indictments	4
Search warrants executed	3
Summary suspensions	8
Monthly Inspection Summary	**Total**
Inspections completed	395
Written Response Required issued	146

Notable Investigative Events

- None.

Executive Director Report

FISCAL

FY26

Fund	Appropriation	Year-to-date Expenditures	Encumbered	Unexpended
OARRS Grants (3HD0)	$ 2,094,643	$ 1,514,967	$ 20	$ 579,656
Medicaid/OARRS Integration (3HH0)	$ 642,117	$ 609,433	$ -	$ 32,684
Equitable Sharing Treasury (3HM0)	$ -	$ 436	$ -	$ (436)
Equitable Sharing Justice (3HN0)	$ -	$ 7,842	$ -	$ (7,842)
Law Enforcement Fund (4A50)	$ 50,000	$ 10,947	$ 1,125	$ 37,928
Operating (4K90)	$ 13,981,441	$ 13,206,901	$ 136,148	$ 638,392
Drug Database Fund (5SG0)	$ 2,826,000	$ 2,574,002	$ 13,630	$ 238,368
All Funds Total	**$ 19,594,201**	**$17,924,528**	**$ 150,923**	**$ 1,518,750**

FY27

Fund	Appropriation	Year-to-date Expenditures	Encumbered	Unexpended
OARRS Grants (3HD0)	$ 2,111,622.00	$ 320,527	$ 25,000	$ 1,766,095
Medicaid/OARRS Integration (3HH0)	$ 645,729.00	$ 508,437	$ -	$ 137,292
Equitable Sharing Treasury (3HM0)	$ -	$ -	$ -	$ -
Equitable Sharing Justice (3HN0)	$ -	$ -	$ -	$ -
Law Enforcement Fund (4A50)	$ 50,000	$ 5,421	$ 1,033	$ 43,546
Operating (4K90)	$ 14,700,319	$ 4,087,362	$ 1,585,732	$ 9,027,225
Drug Database Fund (5SG0)	$ 2,865,000	$ 1,712,125	$ 103,080	$ 1,049,795
All Funds Total	**$ 20,372,670**	**$ 6,633,872**	**$ 1,714,845**	**$12,023,953**

COMMUNICATIONS AND OUTREACH

- Executive Director Schierholt participated in the following:
  - Attended NABP's webinar – The Evolving Landscape of Peptide Compounding
  - Quarterly meeting with the deans
  - NABP District IV Annual Meeting
  - IACP Annual Meeting
  - NASCSA Annual Conference
  - NABP Monthly Executive Officer's Call
  - Held various other meetings with state agencies & leaders

Policy and Communications

HIGHLIGHTS

HB12 **DRUG PRACTICES-RIGHT TO TRY** (GROSS J, SWEARINGEN D) Regarding prescribing, dispensing, and administering drugs and to name this act the Jeff, Dave, and Angie Patient Right to Try Act.
Current Status: 6/11/2025 – **BILL AMENDED**, House Health, (Sixth Hearing)

HB192 **PHARMACY ACCREDITATION, PBM REQUIREMENTS** (BARHORST T, FISCHER T) To limit insurer accreditation requirements for pharmacies, to implement drug cost reporting requirements for pharmacy benefit managers, and to name this act the Community Pharmacy Protection Act.
Current Status: 3/11/2026 - House Insurance, (Sixth Hearing)

HB587 **REGARDING KRATOM PRODUCT SALES** (ODIOSO M, LORENZ B) Regarding sales of kratom products.
Current Status: 3/18/2026 – House Agriculture, (Third Hearing)

HB629 **PRACTICE AUTHORIZATION-PHARMACISTS** (BARHORST T, GROSS J) To authorize pharmacists to treat minor health conditions and to name this act the Pharmacist Prescribing Authority Act.
Current Status: 3/11/2026 – House Health, (First Hearing)

SB209 **PATIENT RIGHT TO TRY ACT** (CUTRONA A, RENYOLDS M) Regarding prescribing, dispensing, and administering drugs and to name this act the Jeff, Dave, and Angie Patient Right to Try Act.
Current Status: 5/28/2025 – Referred to Committee Senate Health

SB230 **AUTHORIZE PHARMACISTS-TREAT CERTAIN RESPIRATORY CONDITIONS** (ROMANCHUK M) Regarding prescribing, dispensing, and administering drugs and to name this act the Jeff, Dave, and Angie Patient Right to Try Act.
Current Status: 6/10/2026 – **PASSED BY SENATE;** Vote 31-2

SB249 **AUTHORIZE DISPENSING IVERMECTIN WITHOUT PRESCRIPTION** (LANG G, JOHNSON T) To authorize the dispensing of ivermectin without a prescription.
Current Status: 4/15/2026 – Senate Health, (Second Hearing)

SB299 **REGARDING KRATOM PRODUCT SALES** (BLESSING III L) Regarding sales of kratom products.
Current Status: 3/24/2026 - Senate General Government, (Second Hearing)